|
12 Oct 2019 |
Slide of the day |
Adverse Effects of Newer Agents 2019 |
|
|
09 Oct 2019 |
Social |
RT @BharatKumarMD: How I feel when I switch a patient from a biologic to a biosimilar. #Rheum https://t.co/6pbdJ3u3U6 |
|
|
08 Oct 2019 |
News |
Biologics Lead the Way in Drug Price Increases |
|
|
30 Sep 2019 |
News |
Ustekinumab Efficacy in Ulcerative Colitis |
|
|
30 Sep 2019 |
News |
FDA Approves Rituximab for Children with GPA |
|
|
27 Sep 2019 |
Social |
Dr. Rob Speira & HSS investigators will lead a multicenter, phase II, 6 mos clinical trial of anti-GM-CSF (mavrilimumab) in patients with giant cell arteritis (GCA. There is still heavy reliance on steroids in GCA; tocilizumab was FDA approved in in 2017 https://t.co/zDWgSVuXec |
|
|
23 Sep 2019 |
Slide of the day |
Biologic Injection Site Reactions |
|
|
17 Sep 2019 |
News |
Anakinra Shows Benefits in Cytokine Storm |
|
|
13 Sep 2019 |
News |
Prior Authorizations Delay Care in Rheumatology |
|
|
27 Aug 2019 |
Social |
Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA |
|
|
27 Aug 2019 |
Social |
Positive safety and efficacy results for subcutaneous infliximab biosimilar, CT-P13 (Remsima), was presented at EULAR 2019. In 48 RA pts, efficacy (DAS28,, ACR20) of CT-P13 SC was comparable to CT-P13-IV up to Week 54. https://t.co/84ismy7ci2 |
|
|
19 Aug 2019 |
Social |
Abbvie has announced that the annual price for its new FDA approved JAK1 inhibitor, Rinvoq, will be $59,000. https://t.co/22LIetdTUh |
|
|
16 Aug 2019 |
News |
Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis |
|
|
14 Aug 2019 |
Social |
Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK |
|
|
13 Aug 2019 |
Social |
RT @RheumNow: In GCA/Temporal arteritis, when do you start a DMARD/Biologic? |
|
|
12 Aug 2019 |
Social |
In GCA/Temporal arteritis, when do you start a DMARD/Biologic? |
|
|
09 Aug 2019 |
Social |
Amgen wins U.S. patent battle against Novartis over Enbrel patents, delaying Novartis' attempts to launch its etanercept biosimilar Erelzi until (possibly) 2029. Novartis intends to appeal. https://t.co/uoEQJJUf9A |
|
|
06 Aug 2019 |
News |
Are Non-TNF Biologics Superior to TNF inhibitors? |
|
|
06 Aug 2019 |
Social |
FDA has approved Turalio (pexidartinib) for the treatment of adults with the rare disorder, tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. https://t.co/eMTmFSW97A |
|
|
04 Aug 2019 |
Social |
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY |
|
